Shengnuo Biotech announced that Shengnuo Pharmaceutical, a wholly-owned subsidiary of the company, signed a “Product Purchase Contract” with a customer earlier to supply GLP-1 polypeptide APIs to the other party. The contract amount was no more than RMB 350,000. The contract execution period was from the date the framework contract was signed to December 31, 2025. After the framework contract was signed, the company actively promoted the relevant cooperation process. Due to the slow progress of commercialization of the contractors' end customer products, the overall execution of the contract was delayed, and product commercialization orders were not actually fulfilled. The company believes that there is a risk that the framework contract may not be fully fulfilled, and investors are kindly requested to pay attention to investment risks.

Shengnuo Biotech announced that Shengnuo Pharmaceutical, a wholly-owned subsidiary of the company, signed a “Product Purchase Contract” with a customer earlier to supply GLP-1 polypeptide APIs to the other party. The contract amount was no more than RMB 350,000. The contract execution period was from the date the framework contract was signed to December 31, 2025. After the framework contract was signed, the company actively promoted the relevant cooperation process. Due to the slow progress of commercialization of the contractors' end customer products, the overall execution of the contract was delayed, and product commercialization orders were not actually fulfilled. The company believes that there is a risk that the framework contract may not be fully fulfilled, and investors are kindly requested to pay attention to investment risks.